Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PEVVH
ADC Name
FDA-018
Synonyms
FDA-018; FDA018; FDA018 Antibody Drug Cojugate; F0024
   Click to Show/Hide
Organization
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
Drug Status
Phase 3
Indication
In total 2 Indication(s)
Breast cancer
Phase 3
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
7.6
Antibody Name
A humanized monoclonal antibody against human Trop-2
  Antibody Info 
Antigen Name
Tumor-associated calcium signal transducer 2 (TROP2)
  Antigen Info 
Payload Name
Active metabolite of irinotecan SN38
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05174637
Phase 1
A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05174637  Clinical Status Phase 1
Clinical Description A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced solid tumors.
References
Ref 1 A PhaseStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA018-ADC in Patients With Advanced Solid Tumors, NCT05174637